ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to support the execution of strategic objectives. The new facility expands the Company’s three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends th ...

Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ETNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET. A live webcast of the fireside chat will be avail ...

PRESS RELEASE Amsterdam, June 2, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company, today announced that it has repurchased 21,765 shares in the period from May 26, 2025 up to and including May 30, 2025. The shares were repurchased at an average price of EUR 23.41 per share for a total consideration of EUR 0.5 million. These repurchases were made as part of the EUR 250 million share buyback programme announced on March 3, 2025. The total number of shares repurchased und ...

Core Insights - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing systemic oncolytic targeted immunotherapies, with its lead candidate CLD-401 presented at the ASCO Annual Meeting [1][2] Group 1: Technology and Innovation - Calidi has developed an enveloped form of its proprietary oncolytic virus that shows greater resistance to immune clearance, enhancing systemic delivery and efficacy in pre-clinical models [2] - The novel genetic modification in CLD-401 incorporates a chimeric CD55 receptor into the virus envelope, which inhibits complement-mediated clearance, improving the virus's stability in circulation [2][4] - The RedTail platform allows for the delivery of genetic payloads directly into the tumor microenvironment, with CLD-401 expressing an IL-15 superagonist to activate and expand natural killer (NK) cells and CD8+ T cells [3][4] Group 2: Strategic Development - Calidi is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug (IND) application in the second half of 2026 [4] - The company is actively seeking strategic partnerships to accelerate clinical development and enhance the impact of its RedTail platform [4][6] - The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs [7]

RESTON, Va., June 02, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), a leader in advanced nuclear fuel technology, today announced the completion of the final design review for its upcoming irradiation experiment, marking a critical step toward advancing its next-generation Lightbridge Fuel™ product. The design review, a required approval before proceeding with the experiment, is a significant milestone in the ongoing collaboration between Lightbridge and the Idaho National Laboratory (INL ...

ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA’ s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration ...

Core Points - The Company announced a monthly distribution of $0.08 per share for June 2025, payable on June 30, 2025 [1] - Future distributions are subject to Board approval and compliance with debt covenants and preferred stock terms [2] - The Company is a non-diversified, closed-end management investment company focused on providing high after-tax total returns through cash distributions [3] - The Company invests at least 80% of its total assets in securities of Energy Infrastructure Companies [3] - Distribution amounts may vary based on portfolio changes and market conditions [4] Distribution Details - Record Date: June 13, 2025 - Payment Date: June 30, 2025 - Distribution Amount: $0.08 - Estimated Return of Capital: 50% [3]

Core Viewpoint - Solar Alliance Energy Inc. reported a decline in revenue for Q1 2025 due to severe weather conditions affecting project timelines, but remains optimistic about future growth in the commercial solar sector [2][3]. Financial Performance - Revenue for Q1 2025 was $835,609, down from $1,604,326 in Q1 2024, reflecting a decrease of approximately 48% [3][7]. - Cost of sales for Q1 2025 was $882,092, compared to $1,014,394 in Q1 2024, resulting in a gross deficit of $46,483, a significant decline from a profit of $585,932 in the previous year [7]. - The net deficit for Q1 2025 was $474,277, contrasting with a net income of $141,303 in Q1 2024 [7]. - Total expenses for Q1 2025 were $424,065, slightly down from $451,188 in Q1 2024 [7]. - The company reported a cash balance of $13,111 as of March 31, 2025 [7]. Business Operations and Strategy - The primary activity in Q1 2025 involved the construction of a large solar project in Kentucky, which faced delays due to severe weather [3]. - The company continues to target larger customers for solar system sales and installations, focusing on utility and commercial sectors, with projects up to 5MWs [5]. - Solar Alliance is committed to servicing small and medium-sized businesses in rural communities while pursuing larger commercial and community solar projects [6]. - The company aims for full-year profitability in 2025, emphasizing opportunities in the Southeast U.S. commercial solar sector [3][6]. Growth Opportunities - Solar Alliance is exploring corporate growth opportunities through partnerships, joint ventures, and other initiatives that align with its profitability and market opportunity criteria [7].

Core Viewpoint - Teck Resources Limited announced mechanical issues at its Carmen de Andacollo (CdA) Operations in Chile, leading to a maintenance shutdown of the SAG mill, but does not expect a material impact on production or sales for 2025 [1][2][3]. Group 1: Production Impact - Production at CdA will be interrupted for approximately one month for repairs, but the company plans to reschedule other maintenance to mitigate the impact [2]. - The previously disclosed guidance for 2025 total annual copper production and for CdA remains unchanged despite the downtime [2]. - An unrelated temporary outage of the shiploader at the Quebrada Blanca (QB) port facility is also expected to last about one month, but operations at the QB mine and plant continue normally [3]. Group 2: Company Overview - Teck is a leading Canadian resource company focused on providing essential metals for economic development and energy transition, with a strong portfolio of copper and zinc operations across North and South America [7]. - The company emphasizes responsible growth and resilience built on stakeholder trust, with shares listed on both the Toronto Stock Exchange and the New York Stock Exchange [7].

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce the appointment of Ignacio Cruz to the Company’s board of directors. Ignacio Cruz is a Civil Engineer with over forty years of experience in leading positions in the Chilean mining, energy, and civil society sectors. Most recently, Mr. Cruz was Executive Chair of TECHO International, Latin America’s largest NGO with operations in 19 countries. Before ...